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A B S T R A C T
Background: Rivaroxaban is an oral anticoagulant that effectively prevents thromboembolic complica-
tions using ﬁxed doses without requiring laboratory monitoring. In this study, we aimed to examine the
coagulation status in patients with non-valvular atrial ﬁbrillation (NVAF) treated with rivaroxaban
compared with warfarin.
Methods and results: The study group consisted of 85 consecutive Japanese patients with NVAF who
received rivaroxaban (n = 33) or warfarin (n = 52) from June 2013 to February 2014. We compared the
coagulation status between the rivaroxaban and warfarin treatments. The prothrombin time (PT) values
did not signiﬁcantly differ between the two groups. However, the prothrombin fragment 1 + 2 (F1 + 2)
level, a marker of thrombin generation, was signiﬁcantly higher in the rivaroxaban group than the
warfarin group (202  88 pmol/l vs. 114  79 pmol/l, p < 0.001). Next, we collected blood samples from 18
patients taking rivaroxaban at 3 h and 15 h after the drug intake and evaluated the time-dependent changes
in the coagulation status. The PT values at 3 h after the drug intake were signiﬁcantly more prolonged than
those at 15 h (p < 0.001). However, there were no signiﬁcant differences in the F1 + 2 levels between the two
time points (194  73 pmol/l [at 3 h] vs. 165  61 pmol/l [at 15 h], p = 0.112).
Conclusions: Our preliminary results suggest that the thrombin generation level is stable regardless of
the time elapsed after rivaroxaban intake, and warfarin treatment may inhibit thrombin generation
more aggressively than rivaroxaban.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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jo u rn al h om ep age: ww w.els evier .c o m/lo c ate / j j c cIntroduction
Rivaroxaban is a non-vitamin K antagonist oral anticoagulant
(NOAC) that inhibits factor Xa (FXa) directly and is used for
anticoagulation in patients with non-valvular atrial ﬁbrillation
(NVAF). The J-ROCKET AF study demonstrated that rivaroxaban
was not inferior to warfarin for the principal safety outcome and
that there was a trend for a reduction in strokes and non-central
nervous system embolisms observed in Japanese patients treated* Corresponding author at: Cardiovascular Division, Faculty of Medicine,
University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
Tel.: +81 29 853 3143; fax: +81 29 853 3143.
E-mail address: ktajiri@md.tsukuba.ac.jp (K. Tajiri).
http://dx.doi.org/10.1016/j.jjcc.2014.08.006
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightswith rivaroxaban [1], which was consistent with the results of the
global ROCKET AF trial [2].
Thrombin generation from its precursor prothrombin is the
central step in coagulation; hence, excess thrombin generation leads
to thrombosis, whereas insufﬁcient thrombin generation can result
in bleeding (reviewed in [3]). Each anticoagulant inhibits the
thrombin generation through different mechanisms; warfarin
targets vitamin K-dependent multiple coagulation factors and
rivaroxaban is a speciﬁc inhibitor of FXa. Rivaroxaban is adminis-
tered once daily and has a peak and trough in its concentration
curve; however, the wide therapeutic window of rivaroxaban allows
the use of ﬁxed doses without any need for laboratory monitoring
[4]. It has been reported that the prothrombin time (PT) and
activated partial thromboplastin time (APTT) are prolonged
depending on the drug plasma concentrations [5]. However, little reserved.
Table 1
Baseline patient characteristics.
Characteristic Rivaroxaban
(n = 33)
Warfarin
(n = 52)
p-value
Age, years (mean  SD) 79.0  9.2 77.5  9.6 0.471
Female, n (%) 16 (48.5) 18 (34.6) 0.203
Body weight, kg (mean  SD) 59.1  10.3 58.1  11.1 0.683
Cardiac failure congestive, n (%) 12 (36.4) 13 (25.0) 0.263
Hypertension, n (%) 15 (45.5) 24 (46.2) 0.950
Diabetes mellitus, n (%) 11 (33.3) 23 (39.7) 0.318
History of a cerebral infarction
(including TIA), n (%)
2 (6.1) 5 (9.6) 0.561
CHADS2 (mean  SD) 1.94  1.09 2.10  1.31 0.570
CHADS2 score, n (%) 0.946
0 2 (6.1) 4 (7.7)
1 10 (30.3) 13 (25.0)
2 12 (36.4) 19 (36.5)
3 9 (27.3) 16 (30.8)
Creatinine (mean  SD) 0.92  0.33 0.91  0.21 0.890
CrCl, ml/min (mean  SD) 55.4  20.9 55.9  21.2 0.916
CrCl, n (%) 0.414
CrCl >50 ml/min 18 (54.5) 33 (63.5)
CrCl 50 ml/min 15 (45.5) 19 (36.5)
SD, standard deviation; TIA, transient ischemic attack; CrCl, creatinine
clearance.
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thrombin generation between its peak and trough phases. Moreover,
the difference in the coagulation status between warfarin and
rivaroxaban treatment is unknown. In this study, we aimed to
examine the coagulation status in the patients with NVAF treated
with rivaroxaban compared with warfarin.
Methods
Study population
This single-center study consisted of 85 consecutive patients
with NVAF who received rivaroxaban (n = 33) or warfarin (n = 52) at
the physician’s discretion, from June 2013 to February 2014 at
Sumiyoshi Clinic Hospital. Patients with stable estimated creatinine
clearance (CrCl) levels of 20 ml/min were considered for enroll-
ment in the study. The CrCl was evaluated using the Cockcroft-Gault
formula: CrCl (ml/min) = ([140  age]  body weight [kg]  [0.85 if
female])/(72  serum creatinine [mg/dl]). The present study proto-
col was approved by the institutional review board. All subjects were
required to give written informed consent.
Data collection
The clinical characteristics of the patients were obtained from
their medical records. The CHADS2 score was calculated as follows:
one point for a history of hypertension, diabetes, or recent heart
failure; and two points for a history of a stroke or transient ischemic
attack (TIA) [6]. The CHADS2-VASc score was calculated as follows:
one point for a history of hypertension, diabetes mellitus, heart
failure, vascular disease (myocardial infarction, complex aortic
plaque, or peripheral artery disease), female gender, or age between
65 and 74 years; and two points for a history of a stroke or TIA, or age
75 years [7]. For all patients, the PT (Coagpia PT-N, Sekisui Medical
Co., Tokyo, Japan), APTT (Coagpia APTT-N, Sekisui Medical Co.) and
prothrombin fragment 1 + 2 (F1 + 2) levels were measured 3 h
following the oral dosing. To evaluate the differences in the time-
dependent changes in the coagulation status in the individual
patients with rivaroxaban treatment, the values of the PT, APTT, and
F1 + 2 were sampled from 18 patients at 3 h and 15 h after the drug
intake on different days.
Clinical major adverse events were deﬁned as all-cause death,
cardiac death, myocardial infarction, or cerebral infarction. Major
bleeding complications were deﬁned as cerebral hemorrhage or
gastrointestinal bleeding.
Time in the therapeutic range
The time in the therapeutic range (TTR) of the PT-international
normalized ratio (INR) is the proportion of the estimated period in
which the PT-INR is within the target range (2.0–3.0 for <70 years,
1.6–2.6 for 70 years) [8] to the total follow-up period. For each
patient receiving warfarin, we retraced the PT-INR values from their
medical records and the TTR was calculated using the method
described by Rosendaal et al. [9]. Using specially programmed
software (Eisai, Tokyo, Japan), we input the successive PT-INR values
of each patient and calculated the TTR. This software automatically
draws lines successively between any two consecutive PT-INR
values during the observation period, and calculates the percentage
of the total time within the target range over the entire period [10].
The total follow-up period was 353.6  96.1 days.
Statistical analysis
Data are expressed as means  standard deviation, medians
[interquartile range (IQR)], or numbers and percentages. Comparisonsbetween the two groups were tested by the unpaired t-test or Mann–
Whitney U-test according to the data distribution with or without
normality. All categorical variables were compared by a chi-square
analysis or Fisher’s exact test. Statistical signiﬁcance was considered
at a level of p < 0.05. All statistics were calculated with JMP software
(SAS Institute, Cary, NC, USA).
Results
Patient characteristics and study drugs
The two groups were well balanced with respect to their
baseline characteristics (Table 1). The mean age of the patients
was 78.1  9.4 years (median, 79 years; range, 52–94 years). In the
rivaroxaban group, a renal dose (10 mg once daily) was adminis-
tered to 15 patients with impaired renal function (CrCl <50 ml/
min). In the rivaroxaban-treated patients with preserved renal
function (18 patients, CrCl 50 ml/min), 12 patients were taking a
regular dose of rivaroxaban (15 mg once daily), but the other 6
were receiving a reduced dose (10 mg) because of an advanced age
(76–87 years). Patients treated with warfarin had a mean TTR of
58.8% and a median TTR of 63.7%. There were two sudden deaths
and one cardiac death due to heart failure out of 52 patients who
were receiving warfarin, whereas there were no clinical major
adverse events in the patients with rivaroxaban during the follow-
up period. There were no major bleeding complications in either
group.
Comparison of the coagulation status between rivaroxaban and
warfarin
Fig. 1 shows the coagulation status in both groups at 3 h after
the drug intake. The mean PT-INR was 2.0  0.6 in the warfarin
group. The PT-INR values in 26 patients (50.0%) were in the
therapeutic range at that time, those in 16 patients (30.8%) were
below the normal range, and those in 10 patients (19.2%) were above
it (Supplemental Fig. S1). The PT and APTT values did not signiﬁcantly
differ between the rivaroxaban group and warfarin group
(23.2  7.7 s vs. 24.9  7.4 s, 36.8  6.0 s vs. 36.8  7.7 s, respective-
ly). However, the F1 + 2 levels were signiﬁcantly higher in the
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Fig. 1. The comparison of the coagulation status between rivaroxaban and warfarin.
The values of the prothrombin time (PT), activated partial thromboplastin time
(APTT), and prothrombin fragment 1 + 2 (F1 + 2) were compared between
rivaroxaban and warfarin. The mean value is indicated by the standard
deviation (error bars). The normal range of the F1 + 2 is 69–229 pmol/l.
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114  79 pmol/l, p < 0.001). In the warfarin group, the F1 + 2 values
in the 26 patients (50.0%) were below the normal range (69–
229 pmol/l). No F1 + 2 values in the rivaroxaban-treated patientswere below the normal range. The F1 + 2 values in the 21 patients
(63.6%) treated with rivaroxaban were within the normal range, and
those in the 22 patients (42.3%) treated with warfarin were also
within the normal range. There was a weak relationship between the
PT and F1 + 2 levels in the warfarin group (R2 = 0.253, p < 0.001), but
not in the rivaroxaban group (R2 = 0.107, p = 0.063). We also found a
weak relationship between the APTT and F1 + 2 levels in the warfarin
group (R2 = 0.119, p = 0.012), but not in the rivaroxaban group
(R2 = 0.069, p = 0.139).
Also, compared to the warfarin-treated patients with a PT-INR
value within the therapeutic range (26 patients, PT-INR 2.0  0.3),
the PT and APTT levels were similar between the rivaroxaban group
and warfarin group (23.2  7.7 s vs. 24.3  4.0 s, 36.8  6.0 s vs.
35.9  5.8 s, respectively). The F1 + 2 levels were signiﬁcantly higher
in the rivaroxaban group than in the warfarin group (202  88 pmol/l
vs. 124  89 pmol/l, p = 0.001). In the patients taking therapeutic
doses of warfarin, the F1 + 2 values in nine patients (34.6%) were
below the normal range and those in three patients (11.5%) were
above the normal range.
Comparisons of the F1 + 2 levels between rivaroxaban and warfarin
according to the renal function, age, and CHADS2 score
Next we assessed whether the effect of anticoagulants on the F1 + 2
levels differed depending on the renal function, age, and CHADS2 score.
As shown in Fig. 2A, the F1 + 2 levels showed a greater decrease in
the warfarin group than in the rivaroxaban group in both the patients
with a preserved renal function (CrCl >50 ml/min; 174  85 pmol/l vs.
90  54 pmol/l) and those with an impaired renal function (CrCl 50 ml/
min; 244  87 pmol/l vs. 156  98 pmol/l). Compared to the rivaroxaban
group,theF1 + 2valuesweredecreasedregardlessoftheageinthewarfarin
group (<75 years; 150  45 pmol/l vs. 77  39 pmol/l, 75 to <85 years;
227  102 pmol/l vs. 111  84 pmol/l, 85 years; 238  89 pmol/l vs.
161  86 pmol/l) (Fig. 2B). Next we divided the patients according to
the CHADS2 score. For each CHADS2 score, the F1 + 2 values were lower
in the warfarin-treated patients than in the rivaroxaban treatment
patients (CHADS2 score  1; 205  89 pmol/l vs. 95  69 pmol/l, CHADS2
score = 2; 194  73 pmol/l vs. 123  92 pmol/l, CHADS2 score  3;
210  112 pmol/l vs. 123  74 pmol/l, CHADS2 score  2;
201  89 pmol/l vs. 123  83 pmol/l, CHADS2 score2; 199  80 pmol/l
vs. 110  82 pmol/l) (Fig. 2C, Supplemental Fig. S2).
We also assessed the relationship between the TTR and F1 + 2
levels in the warfarin-treated group and did not observe any
correlation between them (R2 = 0.002, p = 0.778).
The time-dependent changes in the coagulation status with the
rivaroxaban treatment
We collected blood samples from 18 patients taking rivarox-
aban at 3 h and 15 h after the drug intake and evaluated the time-
dependent changes in the coagulation status. Fig. 3 shows the
effect of rivaroxaban on the coagulation status at the different time
points. The PT values were above the normal range (10.7–12.9 s) in
the majority of samples at both 3 h and 15 h after the drug intake
[PT values in the normal range; 5.6% (n = 1/18), 5.6% (n = 1/18),
respectively]. In contrast, 66.7% (n = 12/18) and 77.8% (n = 14/18)
of the APTT values were within the normal range (24–39 s) at 3 h
and 15 h after dosing, respectively. For the F1 + 2 levels, 66.7%
(n = 12/18) and 88.9% (n = 16/18) were within the normal range at
3 h and 15 h, respectively. No F1 + 2 values were below the normal
range. The PT and APTT values at 3 h after the drug intake were
signiﬁcantly more prolonged than those at 15 h (25.1  7.9 s vs.
16.8  3.6 s, 38.2  6.0 s vs. 33.9  4.9 s, respectively). However,
there was no difference in the F1 + 2 levels between the two time
points [194  73 pmol/l (at 3 h) vs. 165  61 pmol/l (at 15 h),
p = 0.112].
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Fig. 2. Comparisons of the prothrombin fragment 1 + 2 (F1 + 2) levels between
rivaroxaban and warfarin according to the renal function, age, and CHADS2 score.
We assessed the effect of anticoagulants on the F1 + 2 levels according to the renal
function (A), age (B), and CHADS2 score (C). The mean value is indicated by the
standard deviation (error bars). The normal range of F1 + 2 is 69–229 pmol/l.
Fig. 3. The time-dependent changes in the coagulation status with rivaroxaban
treatment. Blood samples were collected at 3 h and 15 h after the drug intake, and
the values of the prothrombin time (PT), activated partial thromboplastin time
(APTT), and prothrombin fragment 1 + 2 (F1 + 2) were evaluated. The mean value is
indicated by the standard deviation (error bars). The normal range of the F1 + 2 is
69–229 pmol/l.
K. Tajiri et al. / Journal of Cardiology 65 (2015) 191–196194
K. Tajiri et al. / Journal of Cardiology 65 (2015) 191–196 195Discussion
The major important ﬁndings of the present study are as
follows: in the NVAF patients, (1) the PT and APTT values did not
signiﬁcantly differ between the rivaroxaban group and warfarin
group; (2) however, the F1 + 2 levels were signiﬁcantly higher in
the rivaroxaban group than in the warfarin group; (3) further-
more, the F1 + 2 levels were signiﬁcantly higher in the rivarox-
aban-treated patients regardless of the renal function, age or
CHADS2 score; (4) although the PT and APTT values differed
depending on the time after the rivaroxaban administration, the
F1 + 2 values did not.
Interestingly, there was no difference in the F1 + 2 levels
according to the time elapsed after the rivaroxaban intake.
However, as in several previous studies, the PT and APTT values
were elevated at the peak drug concentration (3 h following oral
dosing) and decreased at the trough [5,11]. The prolonged PT and
APTT levels indicate a decrease in the quality and/or quantity of
some serum coagulation factors, which are associated with the
drug concentration. On the other hand, F1 + 2 is a highly
sensitive marker for thrombin generation; it is a peptide that is
cleaved when prothrombin is activated and converted to
thrombin and the half-life is 90 min [12,13]. The F1 + 2 levels
directly reﬂect the formation of thrombin that acts as a serine
protease that converts soluble ﬁbrinogen into insoluble strands
of ﬁbrin. In the present study, there was no difference in the
F1 + 2 levels between 3 h and 15 h after the rivaroxaban intake.
This phenomenon may be explained by the presence of
physiological coagulation inhibitors, such as protein C, protein
S, antithrombin, and tissue factor pathway inhibitor (TFPI) [14].
At its peak, rivaroxaban directly inhibits FXa and suppresses
the thrombin generation, and the physiological coagulation
inhibitors are preserved. However, during the trough phase, the
preserved coagulation inhibitors are activated and suppress the
thrombin formation [14]. Thus, rivaroxaban may inhibit throm-
bin formation even in the trough phase, which could be
associated with the favorable results in preventing ischemic
strokes in the J-ROCKET AF trial [1].
Compared to the rivaroxaban group, the F1 + 2 levels were
signiﬁcantly lower in the warfarin group despite the similar PT and
APTT values in both groups. Moreover, one-third of the warfarin-
treated patients had an F1 + 2 value below the normal range, but
that was not the case for the rivaroxaban-treated patients. Thus,
warfarin treatment appeared to result in a stronger inhibition of
thrombin generation than rivaroxaban. Does that mean rivarox-
aban has a worse efﬁcacy and/or is safer than warfarin? This is a
difﬁcult question because of the lack of evidence. It is well known
that an excessive PT prolongation is associated with an increased
risk of a major hemorrhage in warfarin-treated patients [15].
However, there have been no studies that have shown a direct
relationship between an oversuppression of thrombin generation
and hemorrhagic events in anticoagulant therapy. In cardiac
surgery, reduced preoperative F1 + 2 levels are associated with an
increased risk of blood loss [16]. Also, a lower basal thrombin–
antithrombin complex (TAT) level, a marker of the thrombin
generation, has been associated with a greater blood loss in non-
cardiac surgery [17]. From these ﬁndings, excessive suppression of
thrombin generation may lead to major bleeding events with
anticoagulation therapy. The J-ROCKET AF trial demonstrated a
trend toward a reduction in major bleeding events in patients
treated with rivaroxaban [1]. This lower risk of major bleeding
events with rivaroxaban may be explained by the milder inhibition
of thrombin generation than with warfarin. On the other hand, the
trial also showed a trend toward a reduction in strokes and non-
central nervous system embolisms in patients treated with
rivaroxaban [1]. Together with this trial, our results suggest thatan overly suppressed thrombin generation may not only be
unnecessary for the prevention of strokes and systemic embolism,
but also lead to hemorrhagic events in NVAF patients. Further
studies are needed to clarify the relationship between the level of
thrombin generation and hemorrhagic and thrombotic events in
NVAF patients treated with anticoagulants.
The levels of the coagulation markers, such as the D-dimer,
are increased in patients with AF, and warfarin therapy is
effective in decreasing them [18]. However, the D-dimer levels
are still elevated even during appropriate anticoagulation
therapy in some patients, and they are the high-risk patients
who subsequently suffer from thromboembolic and cardiovas-
cular events [19–21]. Although the PT-INR is used to monitor
the treatment effects of warfarin, there is a weak [22] or no
relationship [19,23] between the D-dimer levels and the PT-INR.
Also, we found only a weak or no relationship between the PT or
APTT values and the F1 + 2 levels for both treatments. The PT and
APTT are measured in the laboratory as the time until a clot forms
in vitro and they reﬂect the quality and/or quantity of some
coagulation factors in the blood. On the other hand, the D-dimer
originates from the formation and lysis of cross-linked ﬁbrin
[19], and F1 + 2 is a peptide that is cleaved when prothrombin is
activated and converted to thrombin. Thus, they can be used as
markers of the in vivo coagulation status and may be a more
useful parameter for assessing the coagulation status of the
patients.
Study limitations
There were several limitations to this study. First, the
population in the present study was non-randomized and too
small to draw a deﬁnite conclusion. In particular, the study
subjects were a predominantly elderly population. Second, we did
not obtain the D-dimer, TAT, soluble ﬁbrin, or other values to
assess the coagulation status. We chose F1 + 2 because of its high
sensitivity for detecting thrombin generation [12,13]. Third, we
obtained the data only at 3 h and 15 h after the rivaroxaban intake,
which did not reﬂect the true peak/trough values. To assess the
coagulation status during the trough, blood collection just before
the drug intake is needed. Moreover, because of the wide variation
among patients in regard to their response to and/or the absorption
of drugs, it is unknown whether or not the blood collection time is
optimal for assessing the peak/trough coagulation status [11]. Also,
to evaluate the diurnal variation in thrombin generation, more
frequent blood sampling is needed. Because of the small sample
size and short follow-up period, the number of the patients who
experienced clinical major adverse events and major bleeding
complications was so small that it was unknown whether the
F1 + 2 levels could predict subsequent thrombotic or hemorrhagic
events in NVAF patients during oral anticoagulant therapy. Further
investigation will be necessary to resolve these limitations and to
ensure and enhance our results.
Conclusions
We report the coagulation status in Japanese NVAF patients
treated with rivaroxaban and warfarin in real-world clinical
practice. Our preliminary results indicate that the level of the
thrombin generation was stable regardless of the rivaroxaban
concentration. Although the data are limited, warfarin treatment
may inhibit thrombin generation more aggressively than
rivaroxaban.
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